Our experiments confirmed that both the PDK1 inhibitor UCN-01, and the PI3K inhibitor LY294002, effectively inhibited pAkt signalling in two different ovarian carcinoma cell lines, when used as single drugs and in combination with pertuzumab. This evidence concerns the gene PIK3CA and ovarian carcinoma.